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Abstract: Abstract 
 
Introduction 
Osteoarthritis (OA) is one of the most common forms of arthritis.  There 
is accumulating evidence to suggest that OA is an inflammatory disease of 
the entire synovial joint and has multiple phenotypes.  This presents the 
OA research community with new challenges and opportunities.  The main 
challenge is to understand the root cause of the disease and identify 
differences and similarities between OA phenotypes.  The key opportunity 
is the possibility of developing personalized and individualized 
prevention and treatment strategies for OA patients that havewith 
different forms phenotypes of the disease.  Indeed, it has been suggested 
that this is the era of 'personalized prevention' for OA.  The aim of 
this mini-review paper is to focus on the pathophysiological aspects of 
OA development and progression, review the current concepts and discuss 
the future of personalized medicine for OA.   
 
Method 
The PubMed/MEDLINE bibliographic database was searched using the keywords 
'pathophysiology' and 'osteoarthritis'.  
 
Results 
The PubMed/MEDLINE search yielded more than 12,000 relevant papers. A 
selection of these papers is reviewed here. 
 
Conclusion 
There has been slow but steady progress in our understanding of the 
pathophysiology of OA over the last two decades. However, large gaps 
remain in our knowledge of OA pathogenesis and this impacts negatively on 
patients and drug development pipeline. In the absence of new 
pharmaceutical agents and disease modifying osteoarthritis drugs (DMOADs) 
it is clear that lifestyle modification and physical activity are 
important and may delay the need for surgical intervention. 
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- title : what about "new features in pathophysiology of osteoarthritis" ? 
 
Authors’ response: Thank you for this suggestion, we agree that the title can be 
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and suggest the following: “An Update on the Pathophysiology of Osteoarthritis” 
 
- abstract : It could be structured following the Annals guidelines, and main 
results must be shed in light like chondrosenescence concept, circadian 
clocks disturbance and sleep, place of physical exercise 
 
Authors’ response: Thank you for this excellent suggestion, we have restructured the 
abstract according to the instructions to the authors of Annals of Physical and 
Rehabilitation Medicine. 
 
- introduction line 49, concerning joint destabilization, it is more meniscus 
injury than ligament injury that cause instability, please precise this point 
 
Authors’ response: Thank you, you are right, this has been corrected and the 
meniscus of the knee has been mentioned in that sentence. 
 
- gobal burden of OA, please add a reference at the end of the last paragraph 
"Evan is an updated report ..."  
 
Authors’ response: Thank you, we have followed your suggestion and references 
have been added to the last paragraph. 
 
 
 
- modifiable and non modifiable OA risk factors : page 6, 1st paragraph, weight 
management and lifestyle management seem a bit redundant 
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Abstract 
: Introduction 
Osteoarthritis (OA) is one of the most common forms of arthritis.  There is 
accumulating evidence to suggest that OA is an inflammatory disease of the entire 
synovial joint and has multiple phenotypes.  This presents the OA research 
community with new challenges and opportunities.  The main challenge is to 
understand the root cause of the disease and identify differences and similarities 
between OA phenotypes.  The key opportunity is the possibility of developing 
personalized and individualized prevention and treatment strategies for OA patients 
that havewith different forms phenotypes of the disease.  Indeed, it has been 
suggested that this is the era of ‘personalized prevention’ for OA.  The aim of this 
mini-review paper is to focus on the pathophysiological aspects of OA development 
and progression, review the current concepts and discuss the future of personalized 
medicine for OA.   
Method 
The PubMed/MEDLINE bibliographic database was searched using the keywords 
‘pathophysiology’ and ‘osteoarthritis’.  
Results 
The PubMed/MEDLINE search yielded more than 12,000 relevant papers. A 
selection of these papers is reviewed here. 
Conclusion 
There has been slow but steady progress in our understanding of the 
pathophysiology of OA over the last two decades. However, large gaps remain in our 
knowledge of OA pathogenesis and this impacts negatively on patients and drug 
development pipeline. In the absence of new pharmaceutical agents and disease 
modifying osteoarthritis drugs (DMOADs) it is clear that lifestyle modification and 
physical activity are important and may delay the need for surgical intervention. 
(123865 words) 
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Keywords: Synovial joint; Articular cartilage; Synovoium; Osteoarthritis (OA); 
Pathophysiology; Physical Activity; Physical Rehabilitation 
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Introduction 
Osteoarthritis (OA), also known as osteoarthrosis or degenerative joint 
disease, is an disease of synovial joints (1).  It is characterized by progressive 
deterioration and loss of articular cartilage with concomitant structural and functional 
changes in the entire joint, including the synovium, meniscus (in the knee), 
periarticular ligaments, and subchondral bone (2).  OA is actually one of the most 
common, costly and disabling forms of joint disease, being far more common than 
rheumatoid arthritis (RA) and other forms of joint disease (3).  Cohort studies have 
demonstrated that after age, obesity and metabolic disease are major risk factors for 
the development of OA (4,5).  OA is now generally accepted to be an inflammatory 
and biomechanical whole-organ disease that is influenced by a number of factors 
including joint shape and dysplasia (6), obesity (7), synovitis (8–10), complement 
proteins (11), systemic inflammatory mediators (1,12), inflammaging (13,14), innate 
immunity (15), the low-grade inflammation (16) induced by metabolic syndrome 
(1,17) and diabetes mellitus (18).  However, despite the fact that all joint tissues are 
potentially implicated in disease initiation and progression in OA, it is the articular 
cartilage component that has received the most attention in the context of aging, 
injury and disease (2).  Articular cartilage is a flexible and mechanically compliant 
connective tissue found at the end of long bones in articulating joints and in the 
intervertebral disc (2).  Its main function is to provide a smooth, lubricated surface for 
articulation and to facilitate the transmission of loads with a low frictional coefficient 
(19). Throughout life, cartilage is continually remodeled as chondrocytes replace the 
degraded matrix macromolecules with newly synthesized components, although it is 
recognized that this is an exceptionally slow process in adults; proteoglycan turnover 
can take up to 2 decades whereas the half-life of collagen is estimated to range from 
several decades to more than 100 years (20–22).  Although articular cartilage can 
tolerate a tremendous amount of intensive and repetitive physical stress, it manifests 
a striking inability to heal even a minor injury (2). This makes joints particularly 
sensitive to degenerative processes and the development of OA.  The root cause of 
OA is not completely understood.  However, the biomechanical forces that place 
inappropriate levels of stress on the joints (e.g., excessive or abnormal load bearing, 
postural or orthopedic abnormalities, or traumatic injuries that destabilize the joint are 
thought to interact with other environmental, systemic (i.e. biochemical, metabolic) 
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and genetic factors to contribute to the pathogenesis of OA.  The disease has 
traditionally been defined as a prototypical non-inflammatory arthropathy, but today 
there is compelling evidence to suggest that in addition to being a disease of 
biomechanics (23), it has inflammatory and metabolic components (1,16,24–27). 
 The aim of this concise review article is to provide an update on the 
pathophysiology of OA.  We focus on the pathophysiology and pathogenesis of OA, 
review some of the current concepts in OA research and discuss the future of 
personalized medicine for OA.  In the absence of disease modifying OA drugs 
(DMOADs) , personalized therapy should which is likely to include lifestyle evaluation, 
physical therapy and rehabilitation.  Even if structure modifying drugs for OA are on 
the horizon, it will take decades before we have epidemiological data on efficacy.  
Therefore, as we eagerly anticipate the development of novel DMOADs it would be 
prudent to  and focus on OA prevention rather than treatment.  We will set the scene 
by providing an update on the global burden of OA and the spiraling cost of treatment 
(3) before discussing the pathophysiology of OA and the need for identifying early 
inflammatory events and targeting these alterations (12) to ameliorate the major 
symptoms such as inflammation and pain in OA patients (24). 
 
The Global Burden of OA 
OA is the leading cause of chronic disability globally in individuals older than 
70 years and has been designated a ‘priority disease’ by the World Health 
Organization (WHO) (report WHO/EDM/PAR/2004.73).  OA is one of the ten most 
disabling diseases in industrialized countries.  In the Global Burden of Disease 2010 
study, hip and knee OA was ranked as the 11th highest contributor to global disability 
(3).  The prevalence of OA is set to increase in parallel with the increase in the 
number of people aged 60 years and older and the rise in obesity across the world.  
In the United States alone OA is the highest cause of work loss and affects more 
than 20 million individuals, costing the US economy greater than US$100 billion 
annually (28) (29).  OA represents one of the top 5 healthcare costs in Europe (3).  In 
the United Kingdom a third of people aged 45 and over (8.75 million people) have 
                                                        
3
 http://apps.who.int/iris/bitstream/10665/68769/1/WHO_EDM_PAR_2004.7.pdf  
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 7 
sought treatment for OA, and at least half of these individuals have knee OA (half of 
all people seeking treatment for OA have knee OA).  The number of people in the UK 
with knee OA is estimated to increase to 6.5 million by 2020 (allowing for the 
increasing size of the ageing population and the rising levels of overweight and 
obesity).  In France, the direct and indirect costs of OA have been estimated by Le 
pen et al., in the “COART” France study (30). The authors used a top-down approach 
with nationwide data from 2001 to 2003 and estimated the direct costs of OA at €1.6 
billion, representing approximately 1.7% of the budget of the French health insurance 
system.  The authors reported a 156% increase in direct medical costs compared 
with 1993, which was related to an increase in the number of OA patients (+54%).  In 
Canada 4.5 million (one in six) Canadians aged 15 years and older report having 
arthritis and by 2031, approximately seven million Canadians (one in five) are 
expected to have arthritis.  In Australia OA is the leading cause of chronic pain, 
disability and early retirement due to ill health and AU$2 million people live with OA; 
the annual cost of OA to health system is AU$2 billion AUD in joint replacements for 
OA with AU$1.3 billion paid for welfare payments annually.  There are no up-to-date 
estimates of the global economic cost of OA although a 1997 analysis of the 
economic costs of musculoskeletal disorders in the world’s 5 industrialized countries 
(Australia, Canada, France, United Kingdom, and United States), in which OA was 
the most common of these disorders, found a rising trend of costs that had, by then, 
reached between 1% and 2.5% of the gross national product of these countries (31).  
Even if an updated report of global economic burden had been published more 
recently, it would undoubtedly underestimate the true cost burden to the world’s 
health and social care systems. 
 
Modifiable and Non-Modifiable OA Risk Factors  
Certain factors have been shown to be associated with a greater risk of 
developing OA. According to the US Centers for Disease Control and Prevention4 
and the Mayo Clinic5 some of these risk factors for OA are modifiable whereas others 
are not.  The most important OA risk factors are age, gender, overweight/obesity, 
                                                        
4
 http://www.cdc.gov/arthritis/basics/risk-factors.htm  
5
 http://www.mayoclinic.org/diseases-conditions/osteoarthritis/basics/risk-factors/con-20014749  
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joint trauma/sports injuries (and the consequent joint instability and muscle laxity), 
certain occupations that place repetitive stress on a particular joint, genetics (well 
beyond the scope of this review), bone deformities, metabolic disease (i.e. diabetes), 
endocrine disorders and having previously had other rheumatic diseases such as RA 
and gout.  The risk of developing most types of arthritis increases with age and OA is 
certainly no exception (32).  Gender is another critical risk factor for OA.  Indeed 
most types of arthritis are more common in women and 60% of all people with 
arthritis are women so perhaps it is not surprising that the female sex also represents 
a significant risk factor for OA (33).  It has been hypothesized that leptin may be a 
systemic or local factor that mediates the metabolic link between obesity and OA (33).  
Leptin and other adipocytokines (adipokines) may actually be the missing links 
accounting for the gender disparity toward the disease (34–36). 
Some of the above are non-modifiable risk factors for the development of OA.  
There is clinical evidence to suggest that the risk for developing OA can be mitigated 
and reduced by the following: 
 Wweight management,  and avoiding obesity/overweight,  
 Lifestyle changes for OA patients include weight loss and calorie restriction 
 Mmaintaining high levels of mobility and avoiding sedentary lifestyles. 
The challenge will be  
 Mmanaging comorbidities (i.e. diabetes, cardiovascular diseases) and 
m 
 Mitigating the risks of joint injury.  
Some of the above are likely to influence the course of disease progression.  
Experimental approaches using animal models and clinical studies are needed to 
investigate the underlying mechanisms in order to formulate new OA prevention 
strategies. 
 
Inflammatory Aspects of OA 
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Inflammation is now well accepted as a feature of osteoarthritis but we have 
known about this for 40 years, we just chose to ignore some of the published 
literature.  In a paper published in 1975 George Ehrlich described a cohort of 
predominantly menopausal females who presented with a deforming and 
inflammatory OA, some of whom went on to develop changes characteristic of 
rheumatoid arthritis (RA) (37).  The pioneering work that Ehrlich did in this area was 
well recognized by the WHO because of the work that he did for the organization in 
New York (38) but his work has gained more recognition in recent years and after his 
death in 2014.  Many recent studies have shown the presence of synovitis OA 
patients and demonstrated a direct association between joint inflammation and 
disease progression (1,9,39,40). 
 
New Insights into OA Pathophysiology 
The key pathophysiological mechanisms involved in OA involve some the 
usual suspects, namely the pro-inflammatory (interleukins IL-1β, IL-6, IL-8 and tumor 
necrosis factor α (TNF-α) and pro-catabolic mediators through their signaling 
pathways and the well-characterized effects of nuclear factor κB (NFκB) and 
mitogen-activated protein (MAP) kinase signaling responses plus reprogramming are 
'switching' pathways in transcriptional networks (12).  The inflammatory mediators, 
mechanical and oxidative stress conspire to compromise the function and viability of 
chondrocytes, reprogramming them to undergo hypertrophic differentiation and early 
“senescence”, making them even more sensitive to the effects of pro-inflammatory 
and pro-catabolic mediators. 
 
Cartilage Aging and “Chondrosenescence” 
Aging is a natural and inevitable process that is characterized by nine 
hallmarks (41).  These include genomic instability, telomere attrition, epigenetic 
alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial 
dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular 
communication.  Aging and inflammation are major contributing factors to the 
development and progression of arthritic and musculoskeletal diseases, including OA 
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(42). “Inflammaging” refers to the low-grade inflammation that occurs during 
physiological aging.  As stated earlier, one of the hallmarks of aging is cellular 
senescence.  A characteristic of OA is deviant behavior of chondrocytes in diseased 
articular cartilage (43). OA chondrocytes resemble terminally differentiated 
chondrocytes in the growth plate (44) and actively produce pro-inflammatory 
cytokines and matrix degrading enzymes (45) and these catabolic factors result in 
further cartilage degeneration.  Progressive chondrocyte dysfunction is also 
characterized by expression of senescence-associated markers, erosion of 
chondrocyte telomere length and mitochondrial dysfunction due to oxidative damage 
causing the age related loss of chondrocyte function (46). We have recently 
combined the words “chondrocyte” and “senescence” to introduce the term 
“chondrosenescence”.  In our view “chondrosenescence” defines the age-dependent 
deterioration of chondrocyte function that leads to cartilage dysfunction in OA.  We 
developed this concept to stimulate more mechanistic research on chondrocyte aging.  
We propose that a small number of “senescent chondrocytes” may be able to take 
advantage of the inflammatory tissue microenvironment and the inflammaging and 
immunosenescence that is concurrently occurring in the arthritic joint, further 
contributing to the age-related degradation of articular cartilage, subchondral bone, 
synovium and other tissues (13).  In this framework “chondrosenescence” is 
intimately linked with obesity, lifestyle choices and inflammaging and at the molecular 
level with the disturbed interplay between autophagy and inflammasomes, thus 
contributing to the age-related increase in the prevalence of OA and a decrease in 
the efficacy of articular cartilage repair (47).  Understanding “chondrosenescence” 
and the basic mechanisms by which aging affects articular cartilage and other joint 
tissues should reveal new therapeutic targets for slowing or preventing the 
development of OA (42). 
 
Figure 1 
 
Disruption in Circadian Clocks and Rhythms 
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The circadian rhythm is a 24-hour cycle in the physiological processes of all 
animals.  Circadian rhythm They are strictly set, and tightly regulated; indeed 
circadian rhythms are and endogenously generated, although they can be modulated 
by external cues such as light and dark cycles.  The study of circadian clocks and 
circadian rhythms is starting to make a significant impact on rheumatology, 
orthopedics and cartilage biology (48).  Studies in murine chondrocytes have shown 
that the circadian clock regulates genes controlling key aspects of cartilage 
homeostasis (49).  Indeed the catabolic cytokines implicated in the pathophysiology 
of OA can disrupt the circadian clock and the expression of clock-controlled genes in 
cartilage via an NFкB-dependent pathway (50).  The chondrocyte core clock gene 
and transcription factor BMAL1 is one of the key genes that controls cartilage 
homeostasis and integrity. A new study by Dudek and colleagues shows that BMAL1 
is disrupted in human OA cartilage and in aged mouse cartilage.  The authors also 
show that targeted Bmal1 ablation in murine chondrocytes abolishes their circadian 
rhythm and causes progressive degeneration of articular cartilage.  The BMAL1 gene 
directs the circadian expression of many genes implicated in cartilage homeostasis, 
including those involved in chondrocyte apoptosis, catabolic and anabolic pathways.  
Ablation of this gene decreases expression of the major extracellular matrix-related 
genes Sox9, Acan, and Col2a1.  This is the first study that links BMAL1 to the 
maintenance and repair of articular cartilage.  This paper suggests that circadian 
rhythm disruption is a risk factor for the pathogenesis and progression of 
degenerative joint diseases such as OA.  Clock genes are also believed to regulate 
reactive oxygen species (ROS) homeostasis and oxidative stress responses 
suggesting that disruption of circadian rhythms may exacerbate inflammaging and 
enhance ROS levels and oxidative stress signaling in OA (51). 
 
Sleep Disturbance and Depression in OA 
The relationship between OA and sleep might seem obvious if we focus on 
pain, which clearly is an important part of the equation, but recent research suggests 
that the connection goes beyond pain and OA symptoms. IndeedIndeed, the 
relationship is far more complex and could indeed be reciprocal.  Rather than OA 
causing insomnia, the two conditions are thought to coexist and may be 
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mechanistically linked.  Parmelee et al., have proposed that sleep disturbance in OA 
is linked with pain, disability, and depressive symptoms (52).  Their work highlights 
the link between sleep disturbance, pain and disability in OA.  Although this is a new 
and under-researched area, papers are gradually emerging to support the notion that 
lack of sleep and disease progression are closely linked in humans and animals (53).  
The study by Parmelee and colleagues has identified a new and important point of 
intervention that may provide a new preventive strategy for OA-related functional 
decline among patients whose sleep is disrupted by OA-related pain (52).  Aside 
from sleep disturbance another potentially important factor in OA progression is 
depression.  Depression appears to play a strong role in the sleep-pain linkage, 
particularly when pain is particularly severe.  The unique predictive role of sleep in 
the progression of disability requires further study but may be an important point of 
intervention to prevent OA-related functional decline among persons whose sleep is 
disrupted by OA-related pain.  It will be very interesting to establish whether drugs 
that can improve the quality of sleep might slow disease progression in cohorts of OA 
patients.  Future work in this area should provide further insight into the interplay 
between circadian rhythms and cartilage homeostasis and may reveal new 
therapeutic targets for the treatment of OA. 
On a more practical level, OA patients may wish to explore ways to improve 
their sleep without using sleep aids and sleep medicines that can have undesired 
side effects. However, hormones such as melatonin are being used as a 
pharmacologic aid to sleep, especially in sleep disorders affecting circadian rhythms. 
Interestingly, melatonin has anti-oxidant properties and is thought to modulate the 
pathogenesis of inflammatory autoimmune diseases. However, we know nothing 
about the effects of melatonin on articular cartilage and chondrocytes. 
 
 
These suggestions and sleep strategies may seem trivial but they represent 
good common sense:  
 Not eating a heavy meal before bed – eating a heavy meal before bedtime can 
disrupt sleep rhythms. 
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 Not drinking heavily caffeinated beverages or large quantities of alcohol before 
bed. 
 Not watching television and tablets in the bedroom before sleeping. 
 Keeping the bedroom comfortably cool (65-68 Fahrenheit, 18-20 degrees 
Celsius), quiet and dark (avoiding external light pollution). 
 
 
Exercise and Physical Activity in the Prevention and Management of OA 
According to reports published by the WHO6, we live in a world where the 
population is becoming increasingly overweight, obese and sedentary.  This toxic 
combination is contributing to an increasing burden of long-term conditions that for 
most health services in the world is financially unsustainable.  Whilst obesity is a 
well-known risk factor for many chronic diseases through the metabolic syndrome a 
lack of physical activity is also an independent risk factor, as is the number of hours 
spent sitting or lying (sedentariness) (54). Consequently, healthcare systems around 
the world are developing strategies trying to encourage health and wellness through 
increased levels of daily physical activity.  Physical activity, exercise and sport form a 
continuum of human exertion.  The precise definitions are less important for a public 
health message, which should encourage more people to be more active more of the 
time.  Nonetheless it is appreciated that some of these activities can potentially result 
in joint damage, injury and OA.  In this section we summarize the existing data and 
current opinion. 
Physical activity is essential for optimal health.  It is acknowledged that 
increasing physical activity and reducing sedentary hours would go a long way to 
preserving health (physical and mental) and preventing increasing burden of long-
term conditions.  MoreoverMoreover, it is recognized that physical activity may be 
used as treatment for several chronic diseases whose etiology includes poor lifestyle 
choices. Globally there is an understanding that physical activity and exercise are 
beneficial with much data to support its prescription, however, the exact prescription 
                                                        
6
 http://www.who.int/mediacentre/factsheets/fs311/en/  
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program is yet to be found.  This is fundamental as most healthcare systems around 
the world have shrinking resources and thus it is important to define a 
commissionable product with known effectiveness.  There is increasing appreciation 
of a dichotomy in the effects of exercise and sport on the health of the 
musculoskeletal system and particularly joints.  Non-elite or recreational activities 
typically confer health benefits.  A number of moderate intensity exercises are 
actually recommended for OA patients. 
 
Figure 2 
 
Conversely, participation in elite level activities, particularly contact or collision 
sports, which are associated with injury, are more associated with post-traumatic OA 
(55,56). There is increasingly good evidence that recreational running, as an 
example of a non-contact/collision activity, is not associated with an increased 
prevalence or progression of knee OA (57,58).  These studies suggest that long-
distance running among healthy older individuals is not associated with accelerated 
radiographic OA.  In fact, long-distance running might even have a protective effect 
against joint degeneration.  However, a number of vigorous intensity exercises may 
not be suitable for patients with established OA. 
 
Figure 3 
 
Another important issue that is worthy of discussion is the effect of acute injury 
on lower limbs and the risk of OA development.  The order of prevalence of lower 
limb OA is typically knee, hip and lastly foot and ankle.  However, the association 
with OA in these joints is almost reverse when one considers injury as a key 
etiological factor - it is the ankle that ranks first with nearly 80% of ankle OA being 
post-traumatic in origin.  However, unlike the knee there is a significant latency 
between injury and onset of symptomatic ankle OA (59,60).  Thus for certain joints 
injury is the primary risk factor for the subsequent development of OA, although the 
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mechanisms have yet to be fully elucidated.  It is also appreciated that injury within a 
given ‘node’ of the kinetic chain can predispose to injury elsewhere – so that an 
incompletely rehabilitated ankle sprain may act as a precursor to a subsequent knee 
injury. 
Reviewing the risks and benefits of physical activity and overall 
musculoskeletal health and OA is beyond the scope of a commissioned article 
entitled: “Pathophysiology of Osteoarthritis”.  However, there is an increasing body of 
evidence to suggest that physical activity is essential for cardiovascular, metabolic, 
musculoskeletal and mental health.  A recent systematic review of exercise for knee 
OA extracted data from 54 studies to provide high-quality evidence to indicate that 
land-based therapeutic exercise provides benefits for patients (61).  The study 
reports that short-term benefits were sustained for at least two to six months after 
cessation of formal treatment in terms of reduced knee pain. There was moderate-
quality evidence shows improvement in physical function among people with knee 
OA.  Interestingly, since the participants in the trials that were included in this 
systematic review were aware of the nature of their treatment, this may have 
contributed to their improvement.  Another recent systematic review has evaluated 
the effects of aquatic exercise for people with knee or hip OA. The study provides 
moderate quality evidence that aquatic exercise may have small, short-term, and 
clinically relevant effects on patient-reported pain, disability, and quality of life in 
people with knee and hip OA (62). Promoting and encouraging physical activity in 
older adults at risk for developing OA is important and has been shown to be 
associated with maintained physical function mediated by muscle strength (63).  
Positive effects have been reported across a wide range of physical activities, 
including one of the simplest forms of exercise: walking.  A positive effect has also 
been associated with more daily walking plus intensive diet and exercise among 
adults with painful knee OA (64,65).  This positive effect may be an important 
psychological factor to consider for promoting physical activity among people with 
painful knee OA and  
 
Conclusions 
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It has been over a decade since Wim van den Berg and Johanne Martel-
Pelletier published short papers with the same titleon the “Pathophysiology of 
osteoarthritis” (66,67).  Knowledge of the pathophysiology of OA is rapidly expanding.  
Recently published reviews on OA suggest that the disorder is complex and 
multifactorial, with numerous genetic, biological, and biomechanical components (68).  
OA is now viewed as an inflammatory disease with multiple phenotypes (32).  This 
presents the OA research community with new challenges and opportunities.  The 
key challenge is identifying the differences and similarities between the phenotypes.  
The main opportunity is the possibility of developing personalized and individualized 
prevention and treatment strategies for OA patients with different forms of the 
disease (69,70).  Chronic, low-grade inflammation in OA is now known to contribute 
to symptoms and disease progression and multiple mediators are emerging as 
regulators of this process (12).  However, in the absence of new pharmaceutical 
agents and disease modifying osteoarthritis drugs (DMOADs) it is clear that lifestyle 
modification and physical activity are important and may delay the need for surgical 
intervention.  This concept should be especially relevant to the Annals of Physical 
and Rehabilitation Medicine and the readers of this Special Issue on 
“Osteoarthritis”. 
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Figure Legends 
 
Figure 1. The convergence of ageing, obesity and lifestyle choices in the 
development of inflammaging and chondrosenescence in OA. 
 
Figure 2. Moderate intensity exercises that are recommended for OA patients. 
 
Figure 3. Vigorous intensity exercises that are not suitable for patients with 
established OA. 
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